Kang Stem Biotech is a South Korean biotechnology company founded in 2010. The company specializes in stem cell-based therapies, particularly for treating inflammatory and autoimmune diseases. Kang Stem Biotech has developed innovative treatments that leverage stem cell technology and has engaged in various research and clinical trials to advance its offerings. The company went public on the Korea Exchange in December 2015 and continues to explore new medical applications for its stem cell-based treatments.